Sana Biotechnology to present clinical data on immune-evading islet cell therapy for type 1 diabetes at EASD 2026.

Sana Biotechnology announced it will present clinical data from a first-in-human study using UP421, an allogeneic islet cell therapy engineered with hypoimmune technology, at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan. This therapy aims to treat type 1 diabetes by transplanting cells without the need for immunosuppression, potentially offering a durable treatment option. The presentation is scheduled for October 2, 2026. This development is significant as it represents progress toward a potential cure for type 1 diabetes through engineered cell therapies.